Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Cardiology > ESC 2022 > Anticoagulation > AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?

AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?

Presented by
Dr Mukul Sharma, McMaster University, Canada
Conference
ESC 2022
Trial
Phase 2, AXIOMATIC-SSP
Doi
https://doi.org/10.55788/48d2d809
    Late-breaking findings from the phase 2, dose-ranging AXIOMATIC-SSP trial evaluating milvexian for secondary stroke prevention showed that, although dose response was not observed, there appeared to be benefit for symptomatic ischaemic strokes. Overall safety appeared reassuring.

    Milvexian is a small molecule inhibitor that binds activated factor XI with high affinity and selectivity and may reduce the risk of stroke when added to antiplatelet drugs without significant bleeding. Because genetic variants known to reduce factor XI levels are associated with reduced risk for ischaemic stroke but are not associated with increased intracranial bleeding, the rationale behind the AXIOMATIC-SSP trial (NCT03766581) was to target factor XI.

    In the trial, presented by Dr Mukul Sharma (McMaster University, Canada), participants with a mild-to-moderate acute non-lacunar ischaemic stroke or transient ischaemic attack (TIA) (n=2,366) received dual antiplatelet therapy (75 mg clopidogrel daily for the first 21 days and 100 mg aspirin for 90 days) and were randomised to 1 of 5 doses of milvexian or placebo for 90 days [1]. The primary efficacy endpoint was the composite of ischaemic stroke or incident infarct on brain MRI. Major bleeding was the safety endpoint.

    The primary efficacy endpoint was not different between milvexian and placebo. Milvexian was associated with a numerically lower risk for clinical ischaemic stroke at all doses except 200 mg twice daily, with doses from 25 to 100 mg twice daily showing an approximately 30% relative risk reduction versus placebo (5.5% for placebo; 4.6% for 25 mg once daily; 3.8% for 25 mg twice daily; 4.0% for 50 mg twice daily; 3.5% for 100 mg twice daily; but 7.7% for 200 mg twice daily).

    Major bleeding event rates were similar to placebo (0.6%; 95% CI 0.2–1.5) for milvexian 25 mg once daily (0.6%; 95% CI 0.1–2.2)and twice daily (0.6%; 95% CI 0.1–2.3) but was moderately increased in the 50 mg twice daily (1.5%; 95% CI 0.5–3.6), 100 mg twice daily (1.6%; 95% CI 0.5–3.8), and 200 mg twice daily (1.5%; 95% CI 0.5–3.4) arms. Dr Sharma pointed out that “most major bleeding episodes were gastrointestinal and manageable. There was no increase in severe bleeding or symptomatic intracranial haemorrhage versus placebo, and no fatal bleeding occurred in any arm of the study.”

    1. Sharma M, et al. AXIOMATIC-SSP: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. Hot Line Session 5, ESC Congress 2022, Barcelona, Spain, 26–29 August.

     

    Copyright ©2022 Medicom Medical Publishers



    Posted on